From Podium To Practice – Breast Cancer ESMO Part 2
In this segment, Dr. Wassim Mchayleh reviews the design and objectives of TROPION-Breast02, highlighting how datopotamab deruxtecan (Dato-DxD) is being studied in metastatic breast cancer. He discusses eligibility criteria, emerging activity signals, safety considerations, and how this agent may position itself within the expanding ADC landscape.